AHZ 0.95% $7.26 admedus ltd

News: AHZ Admedus Says Cardiocel 3D And Vascucel Receives European Regulatory Approval, page-439

  1. 5,928 Posts.
    lightbulb Created with Sketch. 311
    "TAVR devices make the procedure more expensive that the conventional surgical approach"

    Do you have any figures to back that up? I noticed later you talk about cost reductions through shorter stay etc, but I'm pretty sure if you take into account costs of the operating theatre and staff, bypass technicians and resources, post op ICU care and so on, costs of conventional open surgical aortic valve replacement are a lot more than transcatheter valve replacements, not to mention comfort.
 
watchlist Created with Sketch. Add AHZ (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.